---
layout: default
title: Ascorbic Acid
parent: Model Prediction Only (L5)
nav_order: 73
evidence_level: L5
indication_count: 10
---

# Ascorbic Acid
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ascorbic Acid: From Its Original Indication (Not Recorded) to Non-Syndromic Esophageal Malformation

## One-Sentence Summary

Ascorbic acid (vitamin C) is a marketed nutritional product in Canada, but its approved indication is not recorded in the available license data.
The TxGNN model predicts it may be effective for **non-syndromic esophageal malformation**, a congenital structural anomaly.
There are **no clinical trials** and **no publications** supporting this prediction, so it rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in the Canadian license data |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 13 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Ascorbic acid is a well-known essential vitamin, and it is known to act as an antioxidant and as a cofactor in collagen synthesis. Its use for the original indication is established, but no link to esophageal malformation has been shown.

The prediction is difficult to justify biologically. Non-syndromic esophageal malformation is a congenital structural anomaly of embryonic development, and a vitamin is unlikely to correct it. The very high score (99.96%, model rank 1204) is most likely a graph-based artifact of network proximity rather than a real therapeutic signal. No mechanistic rationale can be established from the available data.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Five of the 13 authorizations are listed below. Dosage form and approved indication text are not provided in the source data.

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 780634 | VITAMIN C | Not listed | Not listed |
| 2355981 | ASCOR L 500 | Not listed | Not listed |
| 2245214 | VITAMIN C | Not listed | Not listed |
| 2238890 | HOT LEMON RELIEF FOR SYMPTOMS OF COLD AND FLU EXTRA STRENGTH | Not listed | Not listed |
| 2047349 | HOT LEMON RELIEF FOR SYMPTOMS OF COLD AND FLU REGULAR STRENGTH | Not listed | Not listed |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no supporting trials or literature (L5), and there is no plausible mechanism for a vitamin to treat a congenital structural anomaly. It should not be prioritized.

Other predicted indications for this drug have more evidence. For example, "vitamin deficiency disorder" (L3, Proceed with Guardrails) is largely an established nutritional use rather than true repurposing, and "esophageal disease" (L4) has some trial and literature support. Both are worth reviewing separately.

**To proceed, the following is needed:**
- Mechanism of action data (for example, from the DrugBank API)
- Health Canada package insert warnings and contraindications
- Approved indication text for the Canadian licenses, to confirm the original indication
- Any preclinical or clinical evidence linking ascorbic acid to esophageal development, without which this prediction should stay on hold
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

